TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03750318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vital sign monitoring
Description: Each patient will be set up for monitoring on admission. Duration of opioid therapy for post-operative in-patients may range from 1-3 days. Once opioid therapy is no longer required, Aingeal monitoring will be ended and each patient would be encouraged to have at least 1 day Aingeal monitoring to be recorded during the study. De-identified log files will be extracted from the Surveillance Station and reprocessed to produce counts of the number of alarms raised during monitoring. A sample of the data will be reviewed to determine whether cardiac and respiratory alarms are defined as True or False, with an overall Alarm Rate per patient per day and False Positive Alarm Rate per patient per day derived. Vital sign trend graphs for each patient will be produced.
Study: NCT06636305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity intervention
Description: Women in the intervention group were instructed to obtain 10,000 steps per day and 150 minutes of MVPA (defined as physical activity that resulted in a heart rate in the range of 120-170 bmp) per week and were given a physical activity tracker (FitBit Charge HR 2, Fitbit, San Francisco, USA) to self-monitor progress.
Study: NCT05803525

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intra-canal medication protocol
Description: Copious gentle irrigation will be provided without canal instrumentation using 20 mL 1.5% NaOCl in a slow flowing rate by a 27-gauge irrigating side vented needle positioned 2 mm from the root end followed by 20 mL saline.~After root canal dryness using paper points , double antibiotic paste (DAP) containing 500 mg of metronidazole and ciprofloxacin mixed with 0.5 mL polypropylene glycol giving a creamy paste will transported into root canal via lentulo spiral filler positioned 2 mm shorter than the WL apically and to level just below the cement-enamel junction (CEJ) coronally. Access cavity will be sealed response to the initial treatment will be assessed after 3 weeks.(21) In the next visit, If the patient is asymptomatic, the DAP will be removed using 10 mL of NaOCl according to the concentrations mentioned in each study group, followed by copious irrigation with 10 mL of 17% EDTA (22) and normal saline then drying the canals with sterile paper points.
Study: NCT00593931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Description: Functional Magnetic Resonance Imaging without contrast
Study: NCT02475980

Intervention type: BEHAVIORAL
Intervention: Comprehensive contraception counseling
Description: The study intervention will consist of comprehensive contraceptive counseling through a standardized bundle of services, including a 10-minute educational DVD, handouts on contraceptive methods, and one-on-one contraceptive counseling by the PED physician.
Study: NCT02862535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered via intravenous (IV) infusion (approximately 30 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered via intravenous (IV) infusion (approximately 30 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered via intravenous (IV) infusion (approximately 30 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered via intravenous (IV) infusion (approximately 30 minutes)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered via IV infusion on Day 8 of every 5 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered via IV infusion for over 2 hours on Day 1 of each 21-day cycle
Study: NCT02091999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enfortumab vedotin
Description: intravenous (IV) infusion
Study: NCT03246360

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modification for administration mode of cloxacillin antibiotic
Description: For intermittent administration, patients will benefit from cloxacillin treatment in conventional hospitalization, in accordance with national guidelines, at a dose of 150 mg / kg per day in 4 infusions, not exceeding the maximum daily dose of 12 g / day according to.~For continuous administration the same quantity of cloxacillin 150 mg / kg per day, without exceeding the maximum daily dose of 12 g / day, will be delivered by a self-propelled syringe in twice 12 hours. Patients randomly assigned to receive continuous administration will receive a dose of cloxacillin equivalent to the dose administered 4 times daily during iterative administration using a self-pulsating syringe. For the first day of the study, this loading dose will be subtracted from the 150 mg / kg dose to be administered continuously over the remaining 23 hours of the first day of the study and never exceed 12g / day.~Pharmacological dosages will be performed on the third and sixth day in both arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modification for administration mode of cloxacillin antibiotic
Description: For intermittent administration, patients will benefit from cloxacillin treatment in conventional hospitalization, in accordance with national guidelines, at a dose of 150 mg / kg per day in 4 infusions, not exceeding the maximum daily dose of 12 g / day according to.~For continuous administration the same quantity of cloxacillin 150 mg / kg per day, without exceeding the maximum daily dose of 12 g / day, will be delivered by a self-propelled syringe in twice 12 hours. Patients randomly assigned to receive continuous administration will receive a dose of cloxacillin equivalent to the dose administered 4 times daily during iterative administration using a self-pulsating syringe. For the first day of the study, this loading dose will be subtracted from the 150 mg / kg dose to be administered continuously over the remaining 23 hours of the first day of the study and never exceed 12g / day.~Pharmacological dosages will be performed on the third and sixth day in both arms
Study: NCT01722591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiapex device
Description: Cardiapex percutaneous transapical access and closure system
Study: NCT02938416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isokinetic strengthening exercise
Description: Isokinetic strengthening exercise provides muscle training throughout the range of motion of a joint at a pre-set constant speed of angular velocity. It can be performed in an eccentric or concentric way in a controlled manner, and is evidenced to be an effective and safe training method in patients with anterior cruciate ligament reconstruction, burn injury, ankle instability, osteoarthritic knee, and chronic stroke in the past literatures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic strengthening exercise
Description: Isotonic strengthening exercise keeps the tension remained unchanged during the muscle's length changing. As the muscle's force changes via the length-tension relationship during a contraction, an isotonic contraction will keep force constant while velocity changes. There are two types of isotonic contractions: (1) concentric and (2) eccentric. In a concentric contraction, the muscle tension rises to meet the resistance, then remains the same as the muscle shortens. In eccentric, the muscle lengthens due to the resistance being greater than the force the muscle is producing.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: isometric strengthening exercise
Description: home exercise education on isometric quadriceps strengthening on the day of out-patient appointment
Study: NCT02842398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance Master

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Customary Care
Study: NCT04621448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moving Together
Description: Two-way livestreaming virtual group classes will be offered for 1 hour, 2 days/week for 12 weeks to all participants. Classes will be led by a trained instructor who will demonstrate all movements and will provide brief explanations for the goals of movements. Consistent with the in-person program, classes will focus on the 7 guiding principles of Moving Together:~1. repetition with variation (to promote procedural learning);~2. progressive, functional movements (to improve daily function);~3. slow pace and step-by-step instruction (to minimize cognitive demands);~4. participant-centered goal orientation (to enhance personal meaningfulness of movements);~5. body awareness, mindfulness and breathing (to encourage present-centeredness);~6. social interaction (to promote meaningful connection); and~7. positive emotions (to promote feelings of well-being.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moving Together
Description: Two-way livestreaming virtual group classes will be offered for 1 hour, 2 days/week for 12 weeks to all participants. Classes will be led by a trained instructor who will demonstrate all movements and will provide brief explanations for the goals of movements. Consistent with the in-person program, classes will focus on the 7 guiding principles of Moving Together:~1. repetition with variation (to promote procedural learning);~2. progressive, functional movements (to improve daily function);~3. slow pace and step-by-step instruction (to minimize cognitive demands);~4. participant-centered goal orientation (to enhance personal meaningfulness of movements);~5. body awareness, mindfulness and breathing (to encourage present-centeredness);~6. social interaction (to promote meaningful connection); and~7. positive emotions (to promote feelings of well-being.
Study: NCT03758898

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment
Description: Chest physiotherapy and mobilization were applied twice a day, 8 times in total.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Chest physiotherapy and mobilization were applied twice a day, 8 times in total.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Group 2
Description: Only mobilization was applied twice a day, 8 times in total.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2
Description: Only mobilization was applied twice a day, 8 times in total.
Study: NCT01807273

Intervention type: OTHER
Intervention: Walking test
Study: NCT03116139

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: V/Q imaging
Description: Standard of care

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Computed tomography scan
Description: Standard of care
Study: NCT00216151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Zoledronic Acid 4mg, every three months
Study: NCT04498650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQ912
Description: PQ912 50 mg tablets and 150 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQ912
Description: PQ912 50 mg tablets and 150 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets to mimic PQ912 50 mg and 150 mg tablets
Study: NCT02219932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fampridine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT01595919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Ad libitum amounts of beverage at a meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Ad libitum amounts of beverage at a meal
Study: NCT03785418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Risk Factor Modification
Description: Healthy eating, regular exercise and behavioural therapy.
Study: NCT01863888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriflunomide HMR1726
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholestyramine
Description: Pharmaceutical form:powder Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: charcoal
Description: Pharmaceutical form:granule Route of administration: oral
Study: NCT01391234

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: STAT RT planning and delivery workflow
Description: * Patients will receive simulation, planning, quality assurance, and their first treatment in a single day using the STAT RT workflow.~* Patients will receive a total of 1-5 fractions of high dose palliative radiation therapy via TomoTherapy consisting of 5-10 Gray per fraction.~* Data will be collected to evaluate the effectiveness of our novel image co-registration techniques, CT-detector-based exit dose calculations, and infrared patient position monitoring. These novel techniques for image co-registration, radiation dose calculations, and patient position monitoring will not alter or replace standard of care techniques.
Study: NCT02253589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified ASSIST-linked Brief Intervention
Description: Trained counsellors support participant's motivation to reduce or stop khat use in a 20 minute counselling session.
Study: NCT02862535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered via IV infusion (approximately 60 minutes) every 2 weeks
Study: NCT05762978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-Check Dial
Description: Patient will have their NIF measured with In-Check Dial

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inhaler Device
Description: Children will use inhaler per standard of care.
Study: NCT03379428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg loading dose (first dose), followed by 6 mg/kg every 3 weeks, administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg loading dose (first dose), followed by 6 mg/kg every 3 weeks, administered intravenously (IV)
Study: NCT04660409

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood test for serum Adropin
Description: Blood test for serum Adropin

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood test for serum Adropin
Description: Blood test for serum Adropin

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood test for serum Adropin
Description: Blood test for serum Adropin

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood test for serum Adropin
Description: Blood test for serum Adropin

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood test for serum Adropin
Description: Blood test for serum Adropin
Study: NCT03791918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.
Study: NCT01595919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Ad libitum amounts of beverage at a meal
Study: NCT03791918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: 3mg/kg intravenously every 2 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. TACE Drug Protocol were injected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TACE Drug Protocol
Description: lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)
Study: NCT04058431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: Osteopathic manipulative treatment (OMT) is defined as the therapeutic application of manually guided forces by an osteopathic physician to improve physiologic function and/or support homeostasis that has been altered by somatic dysfunction. Somatic (body framework) dysfunction or altered function of related components is observed in the skeletal, arthrodial and myofascial structures, and their related vascular, lymphatic, and neural elements. Techniques can use a direct method where the restrictive barrier is engaged and a final activating force is applied to correct the somatic dysfunction, or an indirect method where the restrictive barrier is disengaged and the dysfunctional body part is moved away from the restrictive barrier until tissue tension is equal in one or all planes and directions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control- No Intervention
Description: This group will refrain from getting OMT while in the study.
Study: NCT03398460

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Survey
Description: Burnout rates before and after the introduction of a bereavement card Burnout rates before and after an ICU rotation for physicians
Study: NCT00849524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISF35
Description: Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10\^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
Study: NCT03763617

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: d-ptfe membrane
Description: Socket preservation using d-ptfe membrane to inhibit the formation of osteoclasts
Study: NCT03677635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Autobiographical Memory Recall
Description: Participants are asked to recall positive autobiographical memories with the assistance of prompts to promote specificity, generalisability and links to the future. The participants will also view a 5min psychoeducation video on the subject of memory specificity and motivation.
Study: NCT02407756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Study: NCT01938521

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Grape Cells (RGC)
Description: Red Grape Cells (RGC) 1000 mg powder once daily by mouth for three month

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Red Grape Cells (RGC))
Description: Placebo (for Red Grape Cells (RGC)) powder manufactured to mimic Red Grape Cells (RGC) 1000 mg powder
Study: NCT01922037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Participants will receive omalizumab for up to 12 months per investigator standard of care and clinical practice.
Study: NCT01436669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Telemonitoring System (The Zodiac, Philips Health care)
Description: Full blood count (FBC) home tele-monitoring system which will allow cancer patients receiving chemotherapy to test their blood count at home (haemoglobin, haematocrit, white cell count and neutrophil count).
Study: NCT01503242

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo allogeneic peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8
Description: Given IV
Study: NCT01710878

Intervention type: DEVICE
Group type: OTHER
Intervention: Intergard Synergy Graft
Study: NCT04523831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin and Doxycycline
Description: Ivermectin 6 mg, 2 tab stat and Doxycycline 100 mg twice daily for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Paracetamol, Vitamin D, Oxygen if indicated, Low molecular weight heparin, dexamethasone if indicated

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Paracetamol, Vitamin D, Oxygen if indicated, Low molecular weight heparin, dexamethasone if indicated
Study: NCT00624975

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peru-15 Vaccine
Description: up to 1 x 10\^9 CFU of Peru-15 given in 5ml single dose vials with 20 ml buffer solution, given once

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25 mL of buffer solution (2.5 g sodium bicarbonate and 1.65 g ascorbic acid per 100mL potable water)
Study: NCT03379428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8 mg/kg loading dose (first dose), followed by 6 mg/kg every 3 weeks, administered intravenously (IV)
Study: NCT00546832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDS-943 (topical diclofenac sodium 4% spray)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04657237

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Paravertebral block
Description: TPVB will be given using high frequency linear U/S transducer, place the U/S ultrasound probe was placed parallel to the vertebral spine at T4, and, T6 level and shifted 2-3 cm laterally to obtain the appropriate visualization. Following the identification of pleura, transverse process and paravertebral space, the needle was inserted in caudocranial direction using in-plane approach. Confirm negative vessel or pleural breach via aspiration then proceed with local anaesthetic 0.25% bupivacaine (20 ml) delivery slowly divided equally at T4and T6; the pleura will be seen to be pushed downward
Study: NCT00338494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: The starting dose of clofarabine will be 10 mg/m2 once a week for 3 weeks repeated every 4 weeks with dose escalations to 15, 20 , 30 and 40 mg/m2/week.